Loading
A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Bevacizumab in ovarian cancer, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer is a phase 1/2 interventional study registered as NCT07042802 by Nanjing Leads Biolabs Co.,Ltd, with 180 participants planned, started 2025-12-02 and due to reach its primary completion in 2027-12-25. Interventions recorded: LBL-024 for Injection, Paclitaxel injection, Bevacizumab injection. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Platinum-resistant ovarian cancer, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Shares Nanjing Leads Biolabs, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Platinum-resistant ovarian cancer, Bevacizumab, Ovarian cancer.
Shares Platinum-resistant ovarian cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Shares Nanjing Leads Biolabs, Bevacizumab.
Shares Nanjing Leads Biolabs, Bevacizumab.
Shares Platinum-resistant ovarian cancer, Bevacizumab, Paclitaxel / nab-paclitaxel, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/